Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02336451
Title A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges
Acronym Ascend-7
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult
Covered Countries USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS

Facility Status City State Zip Country Details
USC Kenneth Norris Comprehensive Cancer Center SC-3 Los Angeles California 90033 United States Details
Stanford Universtiy Medical Center SC-5 Stanford California 94304 United States Details
Memorial Hospital of South Bend South Bend Indiana 46601 United States Details
Dana Farber Cancer Institute SC-12 Boston Massachusetts 02215 United States Details
The Ohio State University Comprehensive Cancer Center Ohio State University Columbus Ohio 43221 United States Details
Southwestern Regional Medical Center Tulsa Oklahoma 74133 United States Details
Seattle Cancer Care Alliance Seattle Washington 98105 United States Details
Novartis Investigative Site Auckland Australia Details
Novartis Investigative Site Leuven 3000 Belgium Details
Novartis Investigative Site Salvador Bahia 41253-190 Brazil Details
Novartis Investigative Site Porto Alegre Rio Grande Do Sul 90610-000 Brazil Details
Novartis Investigative Site Natal RN 59075 740 Brazil Details
Novartis Investigative Site Itajai SC 88301-229 Brazil Details
Novartis Investigative Site Barretos SP 14784 400 Brazil Details
Novartis Investigative Site Sao Paulo SP 01246 000 Brazil Details
Novartis Investigative Site Sao Paulo 01236 030 Brazil Details
Novartis Investigative Site Toronto Ontario M5G 2M9 Canada Details
Novartis Investigative Site Marseille cedex 20 Bouches Du Rhone 13915 France Details
Novartis Investigative Site Paris 75970 France Details
Novartis Investigative Site Rennes 35043 France Details
Novartis Investigative Site Saint-Herblain Cédex 44805 France Details
Novartis Investigative Site Strasbourg Cedex 67091 France Details
Novartis Investigative Site Villejuif Cedex 94805 France Details
Novartis Investigative Site Bad Berka 99437 Germany Details
Novartis Investigative Site Koeln 50937 Germany Details
Novartis Investigative Site Pokfulam Hong Kong Details
Novartis Investigative Site Livorno LI 57124 Italy Details
Novartis Investigative Site Monza MB 20900 Italy Details
Novartis Investigative Site Messina ME 98158 Italy Details
Novartis Investigative Site Milano MI 20133 Italy Details
Novartis Investigative Site Milano MI 20141 Italy Details
Novartis Investigative Site Perugia PG 06129 Italy Details
Novartis Investigative Site Aviano PN 33081 Italy Details
Novartis Investigative Site Parma PR 43100 Italy Details
Novartis Investigative Site Roma RM 00155 Italy Details
Novartis Investigative Site Orbassano TO 10043 Italy Details
Novartis Investigative Site Verona VR 37126 Italy Details
Novartis Investigative Site Napoli 80131 Italy Details
Novartis Investigative Site Seoul Korea 05505 Korea, Republic of Details
Novartis Investigative Site Seoul 03080 Korea, Republic of Details
Novartis Investigative Site Seoul 06351 Korea, Republic of Details
NKI-AVL, Department of Thoracic-Oncology Amsterdam 1066 CX Netherlands Details
Novartis Investigative Site Saint Petersburg 192148 Russian Federation Details
Novartis Investigative Site Singapore 169610 Singapore Details
Novartis Investigative Site Malaga Andalucia 29010 Spain Details
Novartis Investigative Site Barcelona 08041 Spain Details
Novartis Investigative Site Madrid 28034 Spain Details
Novartis Investigative Site Madrid 28040 Spain Details
Novartis Investigative Site Madrid 28222 Spain Details
Novartis Investigative Site Tainan Taiwan ROC 70403 Taiwan Details
Novartis Investigative Site Taipei 10002 Taiwan Details
Novartis Investigative Site Taipei 11217 Taiwan Details
Novartis Investigative Site Istanbul TUR 34098 Turkey Details
Novartis Investigative Site Ankara 06100 Turkey Details
Novartis Investigative Site Sutton Surrey SM2 5PT United Kingdom Details
Novartis Investigative Site Birmingham B9 5SS United Kingdom Details
Novartis Investigative Site London SE1 9RT United Kingdom Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field